DocDollars

Boehringer Ingelheim Pharmaceuticals, Inc.

CT · United States · Reporting entity ID 100000000234

Total reported 2019–2025
$637.5M
#28 of 2,960 reporting companies — 0.8% of all reported industry payments
$119.3M in general payments across 1,407,196 records, plus $518.2M in research funding across 24,150 records.

How it breaks down

General payments $119,273,072
Research funding $518,217,143

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Boehringer Ingelheim Pharmaceuticals, Inc. reported $637.5M to US doctors and teaching hospitals from 2019 to 2025, ranking #28 of 2,960 reporting companies. 81% of that was research funding and 19% general payments such as consulting, speaking, food and travel. 1,407,196 general payment records and 24,150 research records were filed.

Common questions about Boehringer Ingelheim Pharmaceuticals, Inc.

How much has Boehringer Ingelheim Pharmaceuticals, Inc. paid US doctors?

Boehringer Ingelheim Pharmaceuticals, Inc. reported $637,490,215 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $119,273,072 in general payments, $518,217,143 in research funding.

How does Boehringer Ingelheim Pharmaceuticals, Inc. rank among drug and device companies?

It ranks #28 of 2,960 reporting entities by total reported value, about 0.8% of all industry payments in the dataset.

Does a payment from Boehringer Ingelheim Pharmaceuticals, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.